SCHEMBL4638577

SCHEMBL4638577

O=C(C#Cc1ccccc1Cl)c1ncn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1cccnc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.41
GRIN2B Q13224 1/20 0.39
GPBAR1 Q8TDU6 10/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
KDR P35968 1/20 0.36
DHPS P49366 1/20 0.35
CYP2E1 P05181 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2A6 P11509 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2B6 P20813 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
NTRK1 P04629 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4637729 0.91 PTGDR2 (0.41) GPBAR1PTGDR2SMN1; SMN2
SCHEMBL4707915 0.85 IDH1 (0.48) IDH1GPBAR1PTGDR2KDR
SCHEMBL4638576 0.83 IDH1 (0.41) IDH1GRIN2BGPBAR1KDRDHPS
SCHEMBL4637753 0.79 IDH1 (0.47) IDH1GRIN2BPTGDR2SMN1; SMN2
SCHEMBL4637714 0.79 IDH1 (0.54) IDH1PTGDR2NPC1
SCHEMBL4637994 0.78 CFTR (0.43) IDH1GRIN2BGPBAR1KDRSMN1; SMN2
SCHEMBL4637949 0.76 IDH1 (0.39) IDH1GPBAR1PTGDR2SMN1; SMN2
SCHEMBL4637887 0.76 USP2 (0.36) IDH1GPBAR1PTGDR2CYP3A4CYP2D6
SCHEMBL4638053 0.76 ALDH1A1 (0.44) IDH1PTGDR2
SCHEMBL4637813 0.75 IDH1 (0.39) IDH1GPBAR1PTGDR2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501808-B1 TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-07-02 EP disclosed
US-7179804-B2 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2007-02-20 US disclosed
US-20050239776-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-10-27 US disclosed
EP-1501808-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091227-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239776-A1 Tachykinin receptor antagonists TACR2, TACR1, PROKR1 IDH1 4314/4885GRIN2B 506/4885GPBAR1 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.